Immediate HSCT Group for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Apr 2025: Trial registered, NCT06918834
  2. 24 Jul 2025: Trial started, NCT06918834

The trials

NCT06918834: Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

State
Under way
Phase
Phase 2
People
236 planned
Started
24 Jul 2025
Primary completion
1 Apr 2028
Arms
Immediate HSCT Group
Results
None posted
  1. 9 Apr 2025: Trial registered
  2. 24 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.